Mental state: 2c. Specific ‐ average change score for negative symptoms (PANSS ‐ negative short term) · patients with schizophrenia
1 finding from 1 review
Adverse effects: incidence of serious adverse effects. Movement disorders ‐ dyskinesia ‐short‐term · patients with schizophrenia
It is very uncertain whether chlorpromazine changes adverse effects: incidence of serious adverse effects. Movement… compared with clotiapine (very low certainty).
1 finding from 1 review
Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · patients with schizophrenia
It is very uncertain whether chlorpromazine changes leaving the study early: for any reason compared with clotiapine (very low certainty).
1 finding from 1 review
Economic outcomes: Cost of care · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Service utilisation: hospital admission (short term) · patients with schizophrenia
The intervention showed no clear difference in service utilisation: hospital admission (short term) (low certainty).
1 finding from 1 review
Intervention not reported
Global state: clinically important change in global state · patients with schizophrenia
1 finding from 1 review
Intervention not reported
Global state: relapse · patients with schizophrenia
1 finding from 1 review
Intervention not reported
Mental state: clinically important change in mental state · patients with schizophrenia
1 finding from 1 review
Intervention not reported
Adverse effect/event: clinically important extrapyramidal adverse events ‐ akathisia (medium term) · patients with schizophrenia
The intervention showed no clear difference in adverse effect/event: clinically important extrapyramidal adverse… (low certainty).
1 finding from 1 review
Intervention not reported
Adverse effect/event: death · patients with schizophrenia
1 finding from 1 review
Intervention not reported
Leaving the study early: any reason (medium term) · patients with schizophrenia
The intervention showed no clear difference in leaving the study early: any reason (medium term) (low certainty).
1 finding from 1 review
Mental state‐ general Not improved to an important extent · patients with schizophrenia
YOGA showed no clear difference in mental state: clinically important change PANSS ‐ not improved compared with NON‐STANDARD CARE (low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Social functioning: clinically important change SOFS ‐ overall, not improved · patients with schizophrenia
YOGA showed no clear difference in social functioning: clinically important change SOFS ‐ overall, not… compared with NON‐STANDARD CARE (low certainty).
1 finding from 1 review
Adverse effects ‐ any · patients with schizophrenia
1 finding from 1 review
Quality of life/Mental health outcome · patients with schizophrenia
1 finding from 1 review
Physical health: clinically important change · patients with schizophrenia
1 finding from 1 review
Costs (direct and indirect) · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
YOGA probably leads to lower leaving the study early: short term compared with NON‐STANDARD CARE (moderate certainty).
1 finding from 1 review